nach oben

Virchows Archiv

Erschienen in:

24.10.2022 | Review

Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities

verfasst von: Thomas A. Tousseyn, Rebecca L. King, Falko Fend, Andrew L. Feldman, Pierre Brousset, Elaine S. Jaffe

Erschienen in: Virchows Archiv | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Hodgkin lymphoma was the first of the lymphomas to be recognized as a specific disease entity. However, recent studies have highlighted the heterogeneity of the diseases associated with this eponym warranting clarification and refinement of diagnostic terminology. While classic Hodgkin lymphoma (CHL) remains an essentially unchanged diagnostic entity in the 2022 International Consensus Classification of Mature Lymphoid Neoplasms (2022 ICC), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is now renamed nodular lymphocyte predominant B cell lymphoma (NLPBL) in recognition of the distinct pathologic, biologic, and clinical differences. Fan patterns A, B, and C (sharing the presence of evident follicular structures, and retention of a B cell rich background) will be combined in “typical” or grade 1, while the other “variant” patterns, D, E, and F, are considered grade 2. T-cell/histiocyte-rich large B cell lymphoma (THRBCL) is considered part of the “variant” NLPHL continuum.

The entity previously known as “B cell lymphoma, unclassifiable (BCLU), with features intermediate between diffuse large B cell lymphoma (DLBCL) and CHL” has been renamed “mediastinal gray zone lymphoma” (MGZL) in recognition of the importance of the thymic niche in the biology of this tumor. The diagnostic criteria for MGZL have been refined and require both a high tumor cell density and a strongly preserved B cell program.

This article will describe updates on CHL, NLPBL, and MGZL in the recently published 2022 ICC and provide some useful differential diagnostic clues in cases with atypical morphology or immunophenotype.

Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390. https://doi.org/10.1182/blood-2016-01-643569CrossRef

Campo E, Jaffe ES, Cook JR et al (2022) The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. https://doi.org/10.1182/blood.2022015851CrossRef

Jaffe ES, Stein H, Swerdlow SH (2017) Classic Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al (eds) who classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. Int Agency Res Cancer Lyon. pp 435–442

Connors JM, Cozen W, Steidl C et al (2020) Hodgkin lymphoma. Nat Rev Dis Primers 6:61. https://doi.org/10.1038/s41572-020-0189-6CrossRef

Piris MA, Medeiros LJ, Chang K-C (2020) Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology 52:154–165. https://doi.org/10.1016/j.pathol.2019.09.005CrossRef

Jaffe ES (2022) Lymphoma nomenclature - what’s in a name? Br J Haematol 197:539–543. https://doi.org/10.1111/bjh.18063CrossRef

Anagnostopoulos I, Hansmann ML, Franssila K et al (2000) European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96:1889–1899

Nam-Cha SH, Montes-Moreno S, Salcedo MT et al (2009) Lymphocyte-rich classical Hodgkin’s lymphoma: distinctive tumor and microenvironment markers. Mod Pathol 22:1006–1015. https://doi.org/10.1038/modpathol.2009.54CrossRef

Steidl C (2017) Exposing Hodgkin-Reed-Sternberg cells. Blood 129:6–7. https://doi.org/10.1182/blood-2016-11-746701CrossRef

10.

O’Malley DP, Dogan A, Fedoriw Y et al (2019) American Registry of Pathology Expert Opinions: immunohistochemical evaluation of classic Hodgkin lymphoma. Ann Diagn Pathol 39:105–110. https://doi.org/10.1016/j.anndiagpath.2019.02.001CrossRef

11.

Tang H, Wei Q, Ge J et al (2013) IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma. Hum pathol 44:2167–2172. https://doi.org/10.1016/j.humpath.2013.04.011CrossRef

12.

Tzankov A, Bourgau C, Kaiser A et al (2005) Rare expression of T-cell markers in classical Hodgkin’s lymphoma. Mod Pathol 18:1542–1549. https://doi.org/10.1038/modpathol.3800473CrossRef

13.

Kezlarian B, Alhyari M, Venkataraman G et al (2019) GATA3 Immunohistochemical staining in Hodgkin lymphoma: diagnostic utility in differentiating Classic Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and other mimicking entities. Appl Immunohistochem Mol Morphol 27:180–184. https://doi.org/10.1097/PAI.0000000000000581CrossRef

14.

Bosch-Schips J, Granai M, Quintanilla-Martinez L, Fend F (2022) The grey zones of classic Hodgkin lymphoma. Cancers (Basel) 14(3):742. https://doi.org/10.3390/cancers14030742

15.

Weniger MA, Küppers R (2021) Molecular biology of Hodgkin lymphoma. Leukemia 35:968–981. https://doi.org/10.1038/s41375-021-01204-6CrossRef

16.

Perry AM, Smith LB, Bagg A (2021) Classic Hodgkin lymphoma - old disease, new directions: an update on pathology, molecular features and biological prognostic markers. Acta Med Acad 50:110–125. https://doi.org/10.5644/ama2006-124.329CrossRef

17.

Cader FZ, Schackmann RCJ, Hu X et al (2018) Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. Blood 132:825–836. https://doi.org/10.1182/blood-2018-04-843714CrossRef

18.

Aoki T, Chong LC, Takata K et al (2020) Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma. Canc Discov 10:406–421. https://doi.org/10.1158/2159-8290.CD-19-0680CrossRef

19.

Greaves P, Clear A, Owen A et al (2013) Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 122:2856–2863. https://doi.org/10.1182/blood-2013-06-508044CrossRef

20.

Duffield AS, Ascierto ML, Anders RA et al (2017) Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. Blood Adv 1:1324–1334. https://doi.org/10.1182/bloodadvances.2017007260CrossRef

21.

Roemer MGM, Advani RH, Ligon AH et al (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin Lymphoma and predict outcome. J Clin Oncol 34:2690–2697. https://doi.org/10.1200/JCO.2016.66.4482CrossRef

22.

Vrzalikova K, Pugh M, Mundo L, Murray P (2021) The contribution of EBV to the pathogenesis of classical Hodgkin lymphoma. Ann Lymphoma 5:30–30. https://doi.org/10.21037/aol-21-8CrossRef

23.

Wienand K, Chapuy B, Stewart C et al (2019) Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv 3:4065–4080. https://doi.org/10.1182/bloodadvances.2019001012CrossRef

24.

Montgomery ND, Coward WB, Johnson S et al (2016) Karyotypic abnormalities associated with Epstein-Barr virus status in classical Hodgkin lymphoma. Cancer Genet 209:408–416. https://doi.org/10.1016/j.cancergen.2016.08.006CrossRef

25.

Tiacci E, Ladewig E, Schiavoni G et al (2018) Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood 131:2454–2465. https://doi.org/10.1182/blood-2017-11-814913CrossRef

26.

Schmitz R, Hansmann M-L, Bohle V et al (2009) TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 206:981–989. https://doi.org/10.1084/jem.20090528CrossRef

27.

Green MR, Rodig S, Juszczynski P et al (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18:1611–1618. https://doi.org/10.1158/1078-0432.CCR-11-1942CrossRef

28.

Chetaille B, Bertucci F, Finetti P et al (2009) Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113:2765–3775. https://doi.org/10.1182/blood-2008-07-168096CrossRef

29.

Wu R, Sattarzadeh A, Rutgers B et al (2018) The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor. Blood Cancer J 8:e622. https://doi.org/10.1038/bcj.2017.102CrossRef

30.

Oyama T, Ichimura K, Suzuki R et al (2003) Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16–26. https://doi.org/10.1097/00000478-200301000-00003CrossRef

31.

MacLennan KA, Bennett MH, Tu A et al (1989) Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. A study of 1659 patients. Cancer 64:1686–1693. https://doi.org/10.1002/1097-0142(19891015)64:8%3c1686::aid-cncr2820640822%3e3.0.co;2-iCrossRef

32.

Sethi T, Nguyen V, Li S et al (2017) Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Ther Adv Hematol 8:13–20. https://doi.org/10.1177/2040620716676256CrossRef

33.

Montes-Mojarro IA, Steinhilber J, Bonzheim I et al (2018) The pathological spectrum of systemic anaplastic large cell lymphoma (ALCL). Cancers (Basel) 10:107. https://doi.org/10.3390/cancers10040107CrossRef

34.

Parente P, Zanelli M, Sanguedolce F et al (2020) Hodgkin Reed-Sternberg-like cells in non-Hodgkin lymphoma. Diagnostics (Basel) 10(12):1019. https://doi.org/10.3390/diagnostics10121019

35.

Dojcinov SD, Fend F, Quintanilla-Martinez L (2018) EBV-Positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts. Pathogens 7:28. https://doi.org/10.3390/pathogens7010028CrossRef

36.

Quintanilla-Martinez L, Swerdlow S, Tousseyn T et al (2022) New concepts in EBV-associated B, T and NK-cell lymphoproliferative disorders. Virchows Arch. https://doi.org/10.1007/s00428-022-03414-4

37.

Nicolae A, Pittaluga S, Venkataraman G et al (2013) Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage. Am J Surg Pathol 37:816–826. https://doi.org/10.1097/PAS.0b013e3182785610CrossRef

38.

Abukhiran I, Syrbu SI, Holman CJ (2021) Markers of follicular helper T cells are occasionally expressed in T-cell or histiocyte-rich large B-cell lymphoma, classic Hodgkin lymphoma, and atypical paracortical hyperplasiaA diagnostic pitfall for T-cell lymphomas of T follicular helper origin. Am J Clin Pathol 156:409–426. https://doi.org/10.1093/ajcp/aqaa249CrossRef

39.

Karube K, Takatori M, Sakihama S et al (2021) Clinicopathological features of adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. Blood Adv 5:198–206. https://doi.org/10.1182/bloodadvances.2020003201CrossRef

40.

Xiao W, Chen WW, Sorbara L et al (2016) Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. Hum Pathol 55:108–116. https://doi.org/10.1016/j.humpath.2016.04.019CrossRef

41.

King RL, Gupta A, Kurtin PJ et al (2022) Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs classic Hodgkin lymphoma transformation of CLL: does this distinction matter? Blood Cancer J 12:18. https://doi.org/10.1038/s41408-022-00616-6CrossRef

42.

Vandenberghe P, Wlodarska I, Tousseyn T et al (2015) Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin’s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol 2:e55-65. https://doi.org/10.1016/S2352-3026(14)00039-8CrossRef

43.

Buedts L, Wlodarska I, Finalet-Ferreiro J et al (2021) The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. Blood Adv 5:1991–2002. https://doi.org/10.1182/bloodadvances.2020003039CrossRef

44.

Eberle FC, Salaverria I, Steidl C et al (2011) Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol 24:1586–1597. https://doi.org/10.1038/modpathol.2011.116CrossRef

45.

Jaffe ES, Stein H, Swerdlow SH et al (2017) B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. Int Agency Res Cancer Lyon. pp 342–344

46.

Sarkozy C, Hung SS, Chavez EA et al (2021) Mutational landscape of gray zone lymphoma. Blood 137:1765–1776. https://doi.org/10.1182/blood.2020007507CrossRef

47.

Sarkozy C, Chong L, Takata K et al (2020) Gene expression profiling of gray zone lymphoma. Blood Adv 4:2523–2535. https://doi.org/10.1182/bloodadvances.2020001923CrossRef

48.

Oschlies I, Burkhardt B, Salaverria I et al (2011) Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 96:262–268. https://doi.org/10.3324/haematol.2010.030809CrossRef

49.

Pilichowska M, Pittaluga S, Ferry JA et al (2017) Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv 1:2600–2609. https://doi.org/10.1182/bloodadvances.2017009472CrossRef

50.

Wilson WH, Pittaluga S, Nicolae A et al (2014) A prospective study of mediastinal gray-zone lymphoma. Blood 124:1563–1569. https://doi.org/10.1182/blood-2014-03-564906CrossRef

51.

Sarkozy C, Copie-Bergman C, Damotte D et al (2019) Gray-zone lymphoma between cHL and large B-cell lymphoma. Am J Surg Pathol 43:341–351. https://doi.org/10.1097/PAS.0000000000001198CrossRef

52.

Pittaluga S, Nicolae A, Wright GW et al (2020) Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical hodgkin lymphoma. Blood Cancer Discov 1:155–161. https://doi.org/10.1158/2643-3230.BCD-20-0009CrossRef

53.

Vassilakopoulos TP, Piperidou A, Hadjiharissi E et al (2021) Development of classic Hodgkin lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. Leuk Res 100:106479. https://doi.org/10.1016/j.leukres.2020.106479CrossRef

54.

Traverse-Glehen A, Pittaluga S, Gaulard P et al (2005) Mediastinal gray zone lymphoma. Am J Surg Pathol 29:1411–1421. https://doi.org/10.1097/01.pas.0000180856.74572.73CrossRef

55.

Quintanilla-Martinez L, de Jong D, de Mascarel A et al (2009) Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux. France J Hematopath 2:211–236. https://doi.org/10.1007/s12308-009-0053-9CrossRef

56.

Nicolae A, Pittaluga S, Abdullah S et al (2015) EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 126:863–872. https://doi.org/10.1182/blood-2015-02-630632CrossRef

57.

Rosenwald A, Wright G, Leroy K et al (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851–862. https://doi.org/10.1084/jem.20031074CrossRef

58.

Savage KJ, Monti S, Kutok JL et al (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871–3879. https://doi.org/10.1182/blood-2003-06-1841CrossRef

59.

Chapuy B, Stewart C, Dunford AJ et al (2019) Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood 134:2369–2382. https://doi.org/10.1182/blood.2019002067CrossRef

60.

Mottok A, Hung SS, Chavez EA et al (2019) Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood 134:802–813. https://doi.org/10.1182/blood.2019001126CrossRef

61.

Eberle FC, Rodriguez-Canales J, Wei L et al (2011) Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96:558–566. https://doi.org/10.3324/haematol.2010.033167CrossRef

62.

Mason DY, Banks PM, Chan J et al (1994) Nodular lymphocyte predominance Hodgkin’s disease. A distinct clinicopathological entity. Am J Surg Pathol 18:526–530. https://doi.org/10.1097/00000478-199405000-00014CrossRef

63.

Stein H, Swerdlow SH, Gascoyne RD et al (2017) Nodular lymphocyte predominant Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al (eds) WHO classification of tumors of haematopoietic and lymphoid tissues, revised 4th edition. Int Agency Res Cancer Lyon. pp 431–434

64.

Hartmann S, Eichenauer DA (2020) Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology 52:142–153. https://doi.org/10.1016/j.pathol.2019.10.003CrossRef

65.

Prakash S, Fountaine T, Raffeld M et al (2006) IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 30:585–592. https://doi.org/10.1097/01.pas.0000194741.87798.45CrossRef

66.

Thurner L, Hartmann S, Fadle N et al (2020) Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. Nature Commun 11:2465. https://doi.org/10.1038/s41467-020-16375-6CrossRef

67.

Schuhmacher B, Bein J, Rausch T et al (2019) JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma. Haematologica 104:330–337. https://doi.org/10.3324/haematol.2018.203224CrossRef

68.

Hartmann S, Schuhmacher B, Rausch T et al (2016) Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia 30:844–853. https://doi.org/10.1038/leu.2015.328CrossRef

69.

Fan Z, Natkunam Y, Bair E et al (2003) Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 27:1346–1356. https://doi.org/10.1097/00000478-200310000-00007CrossRef

70.

Hartmann S, Eichenauer DA, Plütschow A et al (2013) The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 122:4246–52; quiz 4292. https://doi.org/10.1182/blood-2013-07-515825

71.

Moore EM, Swerdlow SH, Gibson SE (2017) J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Hum Pathol 68:47–53. https://doi.org/10.1016/j.humpath.2017.08.015CrossRef

72.

Huppmann AR, Nicolae A, Slack GW et al (2014) EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol 38:316–324. https://doi.org/10.1097/PAS.0000000000000107CrossRef

73.

Wang S, Medeiros LJ, Xu-Monette ZY et al (2014) Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol 18:203–209. https://doi.org/10.1016/j.anndiagpath.2014.03.007CrossRef

74.

Ott G, Delabie J, Gascoyne RD, et al (2017) T-cell/histiocyte-rich large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. Int Agency Res Cancer Lyon. pp 298–299

Titel: Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities
verfasst von: Thomas A. Tousseyn
Rebecca L. King
Falko Fend
Andrew L. Feldman
Pierre Brousset
Elaine S. Jaffe
Publikationsdatum: 24.10.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 1/2023
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-022-03427-z

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

The international consensus classification of mastocytosis and related entities

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms

Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation

New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders

Extranodal T- and NK-cell lymphomas

Updates on eosinophilic disorders

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie